Intron Biotechnology signs MTA with European biotech firm for 'pHyal20' SC platform
Predicted impact: Low
Material transfer agreement for a platform; no financial terms disclosed.
iNtRON Biotechnology인트론바이오
048530 · KOSDAQ · ₩048530 · 인트론바이오
₩3,050 ₩0 (0.00%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −18.67%
- Market cap
- ₩94B
- Enterprise value
- ₩73B
- P/E
- —
- P/B
- 1.5×
- Dividend yield
- 0.0%
- ROE
- −16.5%
- Net margin
- −141.3%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−56.5% from the high
₩2,250Today: ₩2,950 – ₩3,280₩7,010
Returns
- 1W+1.7%
- 1M+8.3%
- 3M+26.3%
- 6M−19.4%
- YTD−6.2%
- 1Y−18.7%
- Volume today
- 313,688
- 0.6× the 20-day average
- Traded today
- ₩974M
- Listed shares
- 30,891,758
- EPS (12 months)
- −₩332
- Earnings yield −10.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 37 of 100 (50 is a normal day for this stock).
- MomentumStrong7.2% over the last month; the price is above its 20-day average.
- News impactLow2 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
iNtRON Biotechnology stock overview
iNtRON Biotechnology (인트론바이오, KRX: 048530) is listed on KOSDAQ, in the Biotech & Pharma sector. Intron Biotechnology is a Korean biotech company with two main business segments. Its shares closed at ₩3,050 on Oct 27, 2026, unchanged on the day, giving it a market value of ₩94B.
Key facts
- Market cap
- ₩94B
- Sector
- Biotech & Pharma
- Latest price change
- 0.00%
- As of
- Oct 27, 2026
- Main business
- Intron Biotechnology is a Korean biotech company with two main business segments.
Quick answers about iNtRON Biotechnology
- What does iNtRON Biotechnology do?
- Intron Biotechnology is a Korean biotech company with two main business segments. Its New Drug segment develops bacteriophage-based and endolysin-based drugs, built on its itLysin and IMPA platforms, to treat drug-resistant bacterial infections and expand into immune and microbiome-related diseases, and it generates revenue from technology licensing, research services, royalties, and bacteriophage-based animal antibiotic alternatives. Its DR segment develops and sells molecular diagnostic kits for infectious diseases, including COVID-19 and pneumococcal tests, to customers in Korea and about 60 countries overseas.
- What is the market cap of iNtRON Biotechnology?
- The market capitalisation of iNtRON Biotechnology was ₩94B at the close on Oct 27, 2026.
- Who are the largest shareholders of iNtRON Biotechnology?
- According to the latest official filings, the largest reported holders are Yoon Seong-jun (18.82%, as of Aug 27, 2026); Yoon Gyeong-won (2.07%, as of Jun 15, 2026); National Pension Service (1.38%, as of Dec 31, 2023).
- When is the next earnings report from iNtRON Biotechnology?
- Korean companies rarely announce results dates in advance. Based on when iNtRON Biotechnology filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own iNtRON Biotechnology?
- Yes. The National Pension Service held 1.38% of iNtRON Biotechnology shares as of Dec 31, 2023.
Company profile
Intron Biotechnology is a Korean biotech company with two main business segments. Its New Drug segment develops bacteriophage-based and endolysin-based drugs, built on its itLysin and IMPA platforms, to treat drug-resistant bacterial infections and expand into immune and microbiome-related diseases, and it generates revenue from technology licensing, research services, royalties, and bacteriophage-based animal antibiotic alternatives. Its DR segment develops and sells molecular diagnostic kits for infectious diseases, including COVID-19 and pneumococcal tests, to customers in Korea and about 60 countries overseas.
Written by AI from the company's latest annual report.
- Korean name
- 인트론바이오
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 윤성준, 윤경원(각자대표)
- Founded
- Jan 1999
- Listed
- Jan 2011
- Listed shares
- 30,891,758
- Fiscal year ends
- Month 12
- Website
- www.intron.co.kr/
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Intron Biotechnology signs material transfer agreement in Europe for next-generation SC platform 'pHyal20'
Predicted impact: Low
Material transfer agreement for a platform technology; small and vague commercially.
Recent filings
See all- Other management mattersSep 2, 2026
- 5%+ holding reportAug 27, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- 5%+ holding reportJul 21, 2026
- Securities Issuance Results (Voluntary Disclosure)Jul 15, 2026
Titles in Korean until English translations are added.
Also known as: iNtRON Biotechnology / 인트론바이오 / 048530 / KRX:048530
Source: KRX statistical information